Lung and Lobar Lung Transplant

Policy # 00414
Original Effective Date: 05/21/2014
Current Effective Date: 11/09/2020

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services Are Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:
• Benefits are available in the member’s contract/certificate, and
• Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider lung transplantation for carefully selected patients with irreversible, progressively disabling, end-stage pulmonary disease unresponsive to maximum medical therapy to be eligible for coverage.**

Based on review of available data, the Company may consider a lobar lung transplant from a living or deceased donor for carefully selected patients with end-stage pulmonary disease to be eligible for coverage.**

Based on review of available data, the Company may consider lung or lobar lung retransplantation after a failed lung or lobar lung transplant in patients who meet criteria for lung transplantation to be eligible for coverage.**

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers lung or lobar lung transplantation in all other situations to be investigational.*

* ©2020 Blue Cross and Blue Shield of Louisiana
Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Lung and Lobar Lung Transplant

Policy #  00414
Original Effective Date: 05/21/2014
Current Effective Date: 11/09/2020

**Policy Guidelines**

**Contraindications**
The factors below are potential contraindications subject to the judgment of the transplant center:

- Known current malignancy, including metastatic cancer
- Recent malignancy with high risk of recurrence
- Untreated systemic infection making immunosuppression unsafe, including chronic infection
- Other irreversible end-stage diseases not attributed to lung disease
- History of cancer with a moderate risk of recurrence
- Systemic disease that could be exacerbated by immunosuppression
- Psychosocial conditions or chemical dependency affecting ability to adhere to therapy

**Policy specific:**

- Coronary artery disease not amenable to percutaneous intervention or bypass grafting, or associated with significant impairment of left ventricular function*; or
- Colonization with highly resistant or highly virulent bacteria, fungi, or mycobacteria.

*Some patients may be candidates for combined heart and lung transplantation.

Patients must meet United Network for Organ Sharing guidelines for a Lung Allocation Score greater than zero.

**Lung-Specific Guidelines**
Bilateral lung transplantation is typically required when chronic lung infection and disease is present (ie, associated with cystic fibrosis and bronchiectasis). Some, but not all, cases of pulmonary hypertension will require bilateral lung transplantation.

Bronchiolitis obliterans is associated with chronic lung transplant rejection, and thus may be the etiology of a request for lung retransplantation.

**Background/Overview**
Solid organ transplantation offers a treatment option for patients with different types of endstage organ failure that can be lifesaving or provide significant improvements to a patient’s quality of life. Many advances have been made in the last several decades to reduce perioperative complications.
Available data supports improvement in long-term survival as well as improved quality of life particularly for liver, kidney, pancreas, heart, and lung transplants. Allograft rejection remains a key early and late complication risk for any organ transplantation. Transplant recipients require life-long immunosuppression to prevent rejection. Patients are prioritized for transplant by mortality risk and severity of illness criteria developed by Organ Procurement and Transplantation Network and United Network of Organ Sharing.

**Lung Transplant**

In 2019, 39,719 transplants were performed in the United States procured from almost 11,900 deceased donors and 7,400 living donors. Lung transplants were the fourth most common procedure with 2,714 transplants performed from both deceased and living donors in 2019.

End-stage lung disease may derive from different etiologies. The most common indications for lung transplantation are chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, cystic fibrosis, α1-antitrypsin deficiency, and idiopathic pulmonary arterial hypertension. Before consideration for transplant, patients should be receiving maximal medical therapy, including oxygen supplementation, or surgical options, such as lung volume reduction surgery for chronic obstructive pulmonary disease. Lung or lobar lung transplantation is an option for patients with end-stage lung disease despite these measures.

A lung transplant refers to single-lung or double-lung replacement. In a single-lung transplant, only 1 lung from a deceased donor is provided to the recipient. In a double-lung transplant, both the recipient's lungs are removed and replaced by the donor's lungs. In a lobar transplant, a lobe of the donor's lung is excised, sized appropriately for the recipient's thoracic dimensions, and transplanted. Donors for lobar transplant have primarily been living-related donors, with 1 lobe obtained from each of 2 donors (generally friends or family members) in cases for which bilateral transplantation is required. There are also cases of cadaver lobe transplants.

Potential recipients who are 12 years of age and older are ranked according to the Lung Allocation Score. A score may range between 0 and 100 and incorporates predicted survival after transplantation and predicted survival on the waiting list; the Lung Allocation Score takes into consideration the patient's disease and clinical parameters. Waiting list incorporates the Lung Allocation Score, geography, and blood type classifications. Children younger than 12 years old receive a priority for lung allocation. Under this system, children younger than 12 years old with...
Lung and Lobar Lung Transplant

Policy # 00414
Original Effective Date: 05/21/2014
Current Effective Date: 11/09/2020

respiratory lung failure and/or pulmonary hypertension who meet criteria are considered "priority 1", and all other candidates in the age group are considered "priority 2". A lung review board has the authority to adjust scores on appeal for adults and children.

**FDA or Other Governmental Regulatory Approval**

**U.S. Food and Drug Administration (FDA)**

Solid organ transplants are a surgical procedure and, as such, are not subject to regulation by the U.S. Food and Drug Administration (FDA).

The FDA regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation Title 21, parts 1270 and 1271. Solid organs used for transplantation are subject to these regulations.

**Rationale/Source**

A lung transplant consists of replacing all or part of diseased lungs with healthy lung(s) or lobes. Transplantation is an option for patients with end-stage lung disease.

For individuals who have end-stage pulmonary disease who receive a lung transplant, the evidence includes case series and registry studies. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. International registry data on a large number of patients receiving lung transplantation (>50,000) found relatively high patient survival rates, especially among those who survived the first year posttransplant. After adjusting for potential confounding factors, survival did not differ significantly after single- or double-lung transplant. Lung transplantation may be the only option for some patients with end-stage lung disease. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have end-stage pulmonary disease who receive a lobar lung transplant, the evidence includes case series and systematic reviews. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. There are less data on lung lobar transplants than on whole-lung transplants, but several case series have reported reasonably similar survival outcomes between the procedures, and lung lobar transplants may be the only option for patients unable to wait for a whole-lung transplant. A 2017 systematic review found 1-year
Lung and Lobar Lung Transplant

Policy #: 00414
Original Effective Date: 05/21/2014
Current Effective Date: 11/09/2020

Survival rates in available published studies ranging from 50% to 100%. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have a prior lung or lobar transplant who meet criteria for a lung transplant who receive a lung or lobar lung retransplant, the evidence includes case series and registry studies. Relevant outcomes are overall survival, change in disease status, treatment-related mortality and morbidity. Data from registries and case series have found favorable outcomes with lung retransplantation in patients who meet criteria for initial lung transplantation. Given the exceedingly poor survival prognosis without retransplantation of patients who have exhausted other treatments, the evidence of a moderate level of posttransplant survival may be considered sufficient in this patient population. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

**Supplemental Information**
*Practice Guidelines and Position Statements*

**International Society for Heart and Lung Transplantation**

**Initial Transplant**

In 2006, the International Society for Heart and Lung Transplantation published consensus-based guidelines on the selection of lung transplant candidates. The guidelines stated that:

- "Lung transplantation is now a generally accepted therapy for the management of a wide range of severe lung disorders, with evidence supporting the quality of life and survival benefit for lung transplant recipients. However, the number of donor organs available remains far fewer than the number of patients with end-stage lung disease who might potentially benefit from the procedure. It is of primary importance, therefore, to optimize the use of this resource, such that the selection of patients who receive a transplant represents those with realistic prospects of favorable long-term outcomes..."

In 2014, these recommendations were updated for pulmonary vascular disease. The Society recommended including a transplant list for patients with New York Heart Association class III or IV disease, despite 3 months or more of combination therapy. Additional clinical indications included a cardiac index of less than 2 L/min/m², a mean right atrial pressure of greater than 15 mm
Lung and Lobar Lung Transplant

Policy # 00414
Original Effective Date: 05/21/2014
Current Effective Date: 11/09/2020

Hg, and a 6-minute walk distance of fewer than 350 meters. Also recommended for transplant listing were patients with significant hemoptysis, pericardial effusion, or signs of progressive right heart failure. Other common indications for lung transplant include interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, and COPD.

Retransplant
The 2014 guideline update briefly addressed lung retransplantation, with the consensus statement noting that "criteria for candidate selection for lung retransplantation generally mirror the criteria used for selection for initial lung transplantation."

American Thoracic Society et al
Evidence-based recommendations from the American Thoracic Society and 3 international cardiac societies were published in 2011 for the diagnosis and management of patients with idiopathic fibrosis. For appropriately selected patients with idiopathic pulmonary fibrosis, the international guideline panel recommended lung transplantation (strong recommendation, low-quality evidence)

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
Lung transplantation is covered under Medicare when performed in a facility approved by Medicare as meeting institutional coverage criteria. The Centers for Medicare & Medicaid Services have stated that, under certain limited cases, exceptions to the facility-related criteria may be warranted if there is justification and the facility ensures safety and efficacy objectives.

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 1.
Lung and Lobar Lung Transplant

Policy # 00414
Original Effective Date: 05/21/2014
Current Effective Date: 11/09/2020

Table 1. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT00905463</td>
<td>Analysis of Prognosis and Patients Reported Outcomes in Lung Transplant Candidates</td>
<td>272</td>
<td>Mar 2022</td>
</tr>
<tr>
<td>NCT00177918</td>
<td>Prospective Evaluations of Infectious Complication in Lung Transplant Recipients</td>
<td>600</td>
<td>Dec 2025</td>
</tr>
</tbody>
</table>

References

©2020 Blue Cross and Blue Shield of Louisiana
Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Lung and Lobar Lung Transplant

Policy # 00414
Original Effective Date: 05/21/2014
Current Effective Date: 11/09/2020


©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Lung and Lobar Lung Transplant

Policy # 00414
Original Effective Date: 05/21/2014
Current Effective Date: 11/09/2020

Policy History
Original Effective Date: 05/21/2014
Current Effective Date: 11/09/2020
05/01/2014 Medical Policy Committee review
05/21/2014 Medical Policy Implementation Committee approval. New policy.
08/06/2015 Medical Policy Committee review
08/19/2015 Medical Policy Implementation Committee approval. No change to coverage.
08/04/2016 Medical Policy Committee review
08/17/2016 Medical Policy Implementation Committee approval. No change to coverage.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
08/03/2017 Medical Policy Committee review
08/23/2017 Medical Policy Implementation Committee approval. No change to coverage.
10/04/2018 Medical Policy Committee review
10/17/2018 Medical Policy Implementation Committee approval. No change to coverage. Policy reformatted.
10/03/2019 Medical Policy Committee review
10/09/2019 Medical Policy Implementation Committee approval. No change to coverage.
10/01/2020 Medical Policy Committee review

Next Scheduled Review Date: 10/2021

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2019 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Lung and Lobar Lung Transplant

Policy # 00414
Original Effective Date: 05/21/2014
Current Effective Date: 11/09/2020

Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>32850, 32851, 32852, 32853, 32854, 32855, 32856</td>
</tr>
<tr>
<td>HCPCS</td>
<td>S2060, S2061</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>A15.0, C96.5-C96.6, D86.0-D86.3, D86.81-D86.9, E71.39, E80.3, E84.0-E84.9, E88.01-E88.9, I26.01-I26.09, I26.90-I26.99, I27.0-I27.2, I27.82-I27.89, J41.8, J43.0-J43.9, J44.0-J44.9, J47.0-J47.9, J60, J62.0-J62.8, J63.0-J63.6, J64, J65, J66.0-J66.2, J66.6, J68.4, J84.10, J84.111-J84.112, J84.14, J84.81-J84.89, J89.2-J89.3, J99, M32.13, M33.01 M33.11, M33.21, M33.91, M34.0-M34.2, M34.81-89, M34.9, M35.02, P27.0-P27.9, Q21.0, T80.0XXA, T81.40XA-T81.49XS T81.718A, T81.72XA, T81.818A, Z48.24, Z48.280, Z94.2-Z94.3</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Lung and Lobar Lung Transplant

Policy # 00414
Original Effective Date: 05/21/2014
Current Effective Date: 11/09/2020

whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.
Lung and Lobar Lung Transplant

Policy # 00414
Original Effective Date: 05/21/2014
Current Effective Date: 11/09/2020

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.